Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Zynex, Inc. ZYXI
$9.65
-$0.09 (-0.92%)
На 18:01, 12 мая 2023
+86.53%
Потенциал через год
Ранг: 1
Ключевые показатели
-
Marketcap
361056675.00000000
-
week52high
17.25
-
week52low
6.01
-
Revenue
158167000
-
P/E TTM
20
-
Beta
0.59134900
-
EPS
0.52000000
-
Last Dividend
0.30000000
-
Next Earnings Date
26 июл 2023 г. в 10:59
Описание компании
Zynex, Inc., through its subsidiaries, designs, manufactures, and markets medical devices to treat chronic and acute pain; and activate and exercise muscles for rehabilitative purposes with electrical stimulation. The company offers NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation, and neuromuscular electrical stimulation (NMES) device that is marketed to physicians and therapists by field sales representatives; NeuroMove, an electromyography triggered electrical stimulation device; InWave, an electrical stimulation product for the treatment of female urinary incontinence; and E-Wave, an NMES device. It also supplies private labeled products, including electrodes for the delivery of electrical current to the body, and batteries for use in electrotherapy products. In addition, the company distributes Comfortrac/Saunders for cervical traction, JetStream for hot/cold therapy, LSO Back Braces for lumbar support, and knee braces for knee support. Further, it offers Zynex Fluid Monitoring System (CM-1500), a fluid volume monitor, which is a non-invasive medical device for monitoring relative fluid volume changes used in operating and recovery rooms to detect fluid loss during surgery and internal bleeding during recovery; Zynex Wireless Fluid Monitoring System (CM-1600), a noninvasive monitoring device designed to measure relative changes in fluid volume in adult patients; NiCO CO-Oximeter, a laser-based noninvasive co-oximeter; and HemeOx tHb Oximeter, a laser-based total hemoglobin pulse oximeter. The company provides its products for use in pain management and control; stroke and spinal cord injury rehabilitation; hemodynamic monitoring; and pulse oximetry monitoring. It sells its products through direct sales force primarily in the United States. Zynex, Inc. was founded in 1996 and is headquartered in Englewood, Colorado.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| HC Wainwright & Co. | Buy | Buy | 25 февр 2022 г. |
| HC Wainwright & Co. | Buy | Buy | 30 июл 2021 г. |
| B. Riley Securities | Buy | Neutral | 16 июл 2021 г. |
| Northland Capital Markets | Outperform | Market Perform | 09 мар 2021 г. |
| Piper Sandler | Neutral | Overweight | 29 янв 2021 г. |
| Piper Sandler | Neutral | Neutral | 28 окт 2022 г. |
| HC Wainwright & Co. | Buy | Buy | 28 окт 2022 г. |
| Piper Sandler | Overweight | Neutral | 06 янв 2023 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Lucsok Anna | D | 24129 | 223 | 30 янв 2023 г. |
| Sandgaard Thomas | D | 14987118 | 554 | 30 янв 2023 г. |
| MOORHEAD DANIEL J | D | 27499 | 554 | 30 янв 2023 г. |
| Lucsok Anna | D | 23752 | 5536 | 27 янв 2023 г. |
| Lucsok Anna | A | 76682 | 5000 | 27 янв 2023 г. |
| MOORHEAD DANIEL J | D | 26556 | 1269 | 09 янв 2023 г. |
| Sandgaard Thomas | D | 14986175 | 461 | 27 дек 2022 г. |
| MOORHEAD DANIEL J | D | 24388 | 461 | 27 дек 2022 г. |
| Lucsok Anna | D | 14288 | 184 | 27 дек 2022 г. |
| Lucsok Anna | D | 13973 | 1103 | 13 дек 2022 г. |
Новостная лента
Zynex, Inc. (ZYXI) Q1 2023 Earnings Call Transcript
Seeking Alpha
29 апр 2023 г. в 14:49
Zynex, Inc. (NASDAQ:ZYXI ) Q1 2023 Earnings Conference Call April 27, 2023 4:15 PM ET Company Participants Louisa Smith - Investor Relations Thomas Sandgaard - Chairman, President and Chief Executive Officer Anna Lucsok - Chief Operating Officer Donald Gregg - Vice President, Zynex Monitoring Solutions Daniel Moorhead - Chief Financial Officer Conference Call Participants Jeffrey Cohen - Ladenburg Thalmann Adam Maeder - Piper Sandler Yi Chen - H.C. Wainwright Operator Good afternoon, ladies and gentlemen, and welcome to the Zynex First Quarter 2023 Earnings Conference Call.
Zynex Inc. (ZYXI) Beats Q1 Earnings and Revenue Estimates
Zacks Investment Research
27 апр 2023 г. в 19:00
Zynex Inc. (ZYXI) came out with quarterly earnings of $0.04 per share, beating the Zacks Consensus Estimate of $0.01 per share. This compares to earnings of $0.03 per share a year ago.
Zynex, Inc. to Announce First Quarter 2023 Financial Results
PRNewsWire
19 апр 2023 г. в 09:15
ENGLEWOOD, Colo. , April 19, 2023 /PRNewswire/ -- Zynex, Inc. (Nasdaq: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, today announced that the company will report first quarter 2023 financial results on Thursday, April 27, 2023.
Zynex: Seems An Odd Short Target
Seeking Alpha
18 апр 2023 г. в 12:23
Zynex: Seems An Odd Short Target
Zynex soars after 4Q earnings and revenue beat Street estimates
Proactive Investors
13 мар 2023 г. в 15:24
Zynex Inc shares soared after the company posted fourth quarter earnings and revenue that beat Wall Street analyst estimates. For the period ended December 31, 2022, the Englewood, Colorado-based medical device manufacturer reported earnings of $0.20 per share on revenue of $48.8 million.